Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers.
Allard R J V VossenH H van der ZeeN DavelaarA M C MusM B A van DoornE P PrensPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2018)
We did not detect statistically significant changes in inflammatory markers in HSL skin of HS patients receiving apremilast compared with placebo, despite clinical improvement in the apremilast group. Nonetheless, S100A12 and IL-17A were significantly elevated in HSL skin and showed a decrease in response to apremilast. The translational model in clinical trials involving HS clearly needs further improvement.